Pharmacokinetics of (S)-9-[2-(phosophonylmethoxy) ethyl]adenine (PMEA) and zidovudine (AZT) when administered in combination

R. M. Lush; B. Y. Nguyen; K. C. Cundy; S. Bauza; T. Sogocio; J. Stevens; S. C. Piscitelli; D. J. Venzon; R. Yarchoan; W. D. Figg

Pharmacokinetics of (S)-9-[2-(phosophonylmethoxy) ethyl]adenine (PMEA) and zidovudine (AZT) when administered in combination

R. M. Lush, B. Y. Nguyen, K. C. Cundy, S. Bauza, T. Sogocio, J. Stevens, S. C. Piscitelli, D. J. Venzon, R. Yarchoan, W. D. Figg^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

The pharmacokinetics of (S)-9-[2-(phosophonylmethoxy)ethyl]adenine (PMEA) and zidovudine (AZT) were studied in patients receiving combination therapy with these agents. PMEA was administered as a thirty minute infusion three times weekly, and AZT (100 mg) was administered five times daily. The pharmacokinetics of AZT were studied prior to PMEA therapy, during the first week of combination therapy, and in the fourth week of combination therapy. PMEA concentrations were determined using HPLC and AZT concentrations by fluorescence polarization immunoassay. Data from four patients are available for this analysis. No difference was found in the pharmacokinetics of either AZT or PMEA when administered alone or in combination. Median estimates for AZT and PMEA terminal half-life are 0.63 and 1.57 hours, respectively. This study in four patients found no evidence of a drug interaction between AZT and PMEA.

Original language	English
Pages (from-to)	13-18
Number of pages	6
Journal	Journal of Applied Therapeutics
Volume	1
Issue number	1
State	Published - 1996
Externally published	Yes

Keywords

9-(2 phosophonylmethoxyethyl) adenine
AZT
HIV
PMEA
Pharmacokinetics
Zidovudine

Cite this

@article{c360a21411144dfeb71ce010c0249d93,

title = "Pharmacokinetics of (S)-9-[2-(phosophonylmethoxy) ethyl]adenine (PMEA) and zidovudine (AZT) when administered in combination",

abstract = "The pharmacokinetics of (S)-9-[2-(phosophonylmethoxy)ethyl]adenine (PMEA) and zidovudine (AZT) were studied in patients receiving combination therapy with these agents. PMEA was administered as a thirty minute infusion three times weekly, and AZT (100 mg) was administered five times daily. The pharmacokinetics of AZT were studied prior to PMEA therapy, during the first week of combination therapy, and in the fourth week of combination therapy. PMEA concentrations were determined using HPLC and AZT concentrations by fluorescence polarization immunoassay. Data from four patients are available for this analysis. No difference was found in the pharmacokinetics of either AZT or PMEA when administered alone or in combination. Median estimates for AZT and PMEA terminal half-life are 0.63 and 1.57 hours, respectively. This study in four patients found no evidence of a drug interaction between AZT and PMEA.",

keywords = "9-(2 phosophonylmethoxyethyl) adenine, AZT, HIV, PMEA, Pharmacokinetics, Zidovudine",

author = "Lush, {R. M.} and Nguyen, {B. Y.} and Cundy, {K. C.} and S. Bauza and T. Sogocio and J. Stevens and Piscitelli, {S. C.} and Venzon, {D. J.} and R. Yarchoan and Figg, {W. D.}",

year = "1996",

language = "English",

volume = "1",

pages = "13--18",

journal = "Journal of Applied Therapeutics",

issn = "1072-1754",

number = "1",

}

TY - JOUR

T1 - Pharmacokinetics of (S)-9-[2-(phosophonylmethoxy) ethyl]adenine (PMEA) and zidovudine (AZT) when administered in combination

AU - Lush, R. M.

AU - Nguyen, B. Y.

AU - Cundy, K. C.

AU - Bauza, S.

AU - Sogocio, T.

AU - Stevens, J.

AU - Piscitelli, S. C.

AU - Venzon, D. J.

AU - Yarchoan, R.

AU - Figg, W. D.

PY - 1996

Y1 - 1996

N2 - The pharmacokinetics of (S)-9-[2-(phosophonylmethoxy)ethyl]adenine (PMEA) and zidovudine (AZT) were studied in patients receiving combination therapy with these agents. PMEA was administered as a thirty minute infusion three times weekly, and AZT (100 mg) was administered five times daily. The pharmacokinetics of AZT were studied prior to PMEA therapy, during the first week of combination therapy, and in the fourth week of combination therapy. PMEA concentrations were determined using HPLC and AZT concentrations by fluorescence polarization immunoassay. Data from four patients are available for this analysis. No difference was found in the pharmacokinetics of either AZT or PMEA when administered alone or in combination. Median estimates for AZT and PMEA terminal half-life are 0.63 and 1.57 hours, respectively. This study in four patients found no evidence of a drug interaction between AZT and PMEA.

AB - The pharmacokinetics of (S)-9-[2-(phosophonylmethoxy)ethyl]adenine (PMEA) and zidovudine (AZT) were studied in patients receiving combination therapy with these agents. PMEA was administered as a thirty minute infusion three times weekly, and AZT (100 mg) was administered five times daily. The pharmacokinetics of AZT were studied prior to PMEA therapy, during the first week of combination therapy, and in the fourth week of combination therapy. PMEA concentrations were determined using HPLC and AZT concentrations by fluorescence polarization immunoassay. Data from four patients are available for this analysis. No difference was found in the pharmacokinetics of either AZT or PMEA when administered alone or in combination. Median estimates for AZT and PMEA terminal half-life are 0.63 and 1.57 hours, respectively. This study in four patients found no evidence of a drug interaction between AZT and PMEA.

KW - 9-(2 phosophonylmethoxyethyl) adenine

KW - AZT

KW - HIV

KW - PMEA

KW - Pharmacokinetics

KW - Zidovudine

UR - http://www.scopus.com/inward/record.url?scp=0030318236&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030318236

SN - 1072-1754

VL - 1

SP - 13

EP - 18

JO - Journal of Applied Therapeutics

JF - Journal of Applied Therapeutics

IS - 1

ER -

Pharmacokinetics of (S)-9-[2-(phosophonylmethoxy) ethyl]adenine (PMEA) and zidovudine (AZT) when administered in combination

Abstract

Keywords

Fingerprint

Cite this